Health Canada has instituted numerous measures to help address and combat COVID-19, from facilitating access to COVID-19 products to protecting the public from false or misleading advertisements claiming to prevent, treat or diagnose COVID-19 (see our previous bulletins on these issues in the “Health Canada's response to COVID-19” section).
Given the extensive measures instituted, Health Canada has also published documents summarizing its various measures. Health Canada’s regulatory response to COVID-19: Access to health products is one particularly helpful document.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada – COVID-19 update highlights
Health Canada has again released a flurry of COVID-19 related materials.Read More -
2020 Highlights in Canadian Life Sciences IP and Regulatory Law
In 2020, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
First year of Project Orbis leads to 38 approvals of cancer therapies, including 8 by Health Canada
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence recently published an overview of Project Orbis and the regulatory actions within the first year of its implementation (June 2...Read More